GlassScriptPhysician profile
David A Laub
NPI 1013187764
$34,257.06
in general payments reported to CMS, 2019-2025
25 companies · $1,805 in 2025
The $1,805 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $5,658 · 2021: $48.14 · 2022: $10K · 2023: $680 · 2024: $1,365 · 2025: $1,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,690 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $930 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,690.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $930.00 |
| Education | $229.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $21,005.01 | 2019-2025 | Dysport |
| Dermira, INC. | $5,787.07 | 2019 | |
| Allergan, INC. | $4,610.91 | 2019-2022 | |
| Pfizer INC. | $572.19 | 2023-2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $534.27 | 2019-2025 | Fraxel |
| Abbvie INC. | $307.74 | 2019-2025 | |
| Janssen Biotech, INC. | $234.97 | 2023-2025 | Tremfya |
| Leo Pharma INC. | $137.52 | 2019-2024 | Adbry |
| Amgen INC. | $130.93 | 2022-2023 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $125.00 | 2023 | Ilumya |
| Incyte Corporation | $104.38 | 2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $82.31 | 2023-2025 | Zoryve |
| Edap Technomed INC | $75.00 | 2024 | |
| Endo Pharmaceuticals INC. | $67.57 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $57.31 | 2025 | Daxxify |
| Merz North America, INC. | $53.41 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $50.45 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.98 | 2020 | |
| Astellas Pharma US INC | $32.86 | 2025 | Xtandi |
| Almirall LLC | $31.16 | 2025 | Klisyri |
| Lilly USA, LLC | $25.14 | 2024 | Taltz |
| Aclaris Therapeutics, INC. | $24.70 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $21.68 | 2020 | |
| Strata Skin Sciences, INC. | $16.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Laub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.